Oncology ESMO25: Perspective on ‘inside-out oncology’ and targeted al... Perspective Therapeutics is advancing image‑guided, targeted alpha‑particle therapies (TATs). We spoke to Thijs Spoor at ESMO 2025 to find out more.
Oncology How blood tests can inform cancer treatment decisions, with ... Craig Eagle, chief medical officer of Guardant Health, discusses blood as a rich source of biomarker development in cancer prognosis.
Oncology Radiopharmaceutical innovation: Giving cancer drugs second c... Molecular recycling could transform the economics and innovation of oncology drug discovery.
Oncology ESMO 2025 in review: A new era in oncology, from AI to next-... ESMO 2025 reflected a field in the midst of rapid evolution – one that is increasingly defined by personalisation and data-driven decision-making.
Oncology Delving into the physics of cancer, with Lew Bender In a new podcast, Intensity Therapeutics' Lew Bender discusses intra-tumourally injected therapeutics - a novel approach to cancer cell death.
Oncology Targeting blood cancers with high unmet need When it comes to myeloid malignancies such as acute myeloid leukaemia (AML) and myelodysplastic syndrome (MDS), treatment progress has been slow.
News Padcev/Keytruda scores again in early bladder cancer Pfizer and Astellas now have two studies supporting the use of Padcev with MSD's Keytruda as perioperative therapy for muscle-invasive bladder cancer.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.